PEPTIDE
Verified ComparisonLast updated: 20 March 2026

Semaglutide vs AOD-9604

Semaglutide is an established GLP-1 agonist approved for weight management. AOD-9604 targets HGH-mediated fat loss.

Compound A

Semaglutide

Metabolic

Evidence
4.3/ 5
A−

Compound B

AOD-9604

Metabolic

Evidence
3.7/ 5
B
Editor's note
Semaglutide is approved; AOD-9604 is investigational.
CriterionSemaglutideAOD-9604
MechanismGLP-1 receptor agonismHGH lipid-metabolism mimicry
Regulatory statusApproved (multiple countries, AU)Investigational
Clinical evidenceExtensiveLimited
Weight loss magnitudeSubstantial (15-22%)Moderate
Lipid preservationVariableLipid-selective

Frequently asked questions

Semaglutide for approved/clinical contexts; AOD-9604 for investigational weight-loss research.

Want to read the full reviews?